Parvifloron D from Plectranthusstrigosus: Cytotoxicity Screening of Plectranthus spp. Extracts. by Garcia, Catarina et al.
biomolecules
Article
Parvifloron D from Plectranthus strigosus:
Cytotoxicity Screening of Plectranthus spp. Extracts
Catarina Garcia 1,2, Epole Ntungwe 1,2 , Ana Rebelo 1,2, Cláudia Bessa 3 , Tijana Stankovic 4,
Jelena Dinic 4 , Ana Díaz-Lanza 2 , Catarina P. Reis 5 , Amílcar Roberto 1, Paula Pereira 1,6,
Maria-João Cebola 1,6, Lucília Saraiva 3 , Milica Pesic 4 , Noélia Duarte 5,* and
Patrícia Rijo 1,5,*
1 Research Center for Biosciences & Health Technologies (CBIOS), Universidade Lusófona de Humanidades e
Tecnologias, 1749-024 Lisboa, Portugal; catarina.g.garcia@gmail.com (C.G.);
ntungweepolengolle@yahoo.com (E.N.); ana.rebelo1490@gmail.com (A.R.);
amilcar.roberto@ulusofona.pt (A.R.); paulapereira1@sapo.pt (P.P.); m.joao.cebola@gmail.com (M.-J.C.)
2 Department of Biomedical Sciences, Faculty of Pharmacy, University of Alcalá, Campus Universitario,
28871 Alcalá de Henares, Spain; ana.diaz@uah.es
3 LAQV/REQUIMTE, Laboratório de Microbiologia, Departamento de Ciências Biológicas, Faculdade de
Farmácia, Universidade do Porto, Rua de Jorge Viterbo Ferreira n. 228, 4050-313 Porto, Portugal;
claudiasantos26@gmail.com (C.B.); lucilia.saraiva@ff.up.pt (L.S.)
4 Institute for Biological Research, “Siniša Stankovic´”, University of Belgrade, Despota Stefana 142,
11060 Belgrade, Serbia; tijana.andjelkovic@ibiss.bg.ac.rs (T.S.); jelena.dinic@ibiss.bg.ac.rs (J.D.);
camala@ibiss.bg.ac.rs (M.P.)
5 Instituto de Investigação do Medicamento (iMed.ULisboa), Faculdade de Farmácia, Universidade de Lisboa,
1649-003 Lisboa, Portugal; catarinareis@ff.ulisboa.pt
6 CERENA–Centre for Natural Resources and the Environment, Instituto Superior Técnico (IST),
Universidade de Lisboa, Av. Rovisco Pais, 1049-001 Lisbon, Portugal
* Correspondence: mduarte@ff.ulisboa.pt (N.D.); patricia.rijo@ulusofona.pt (P.R.)
Received: 23 September 2019; Accepted: 13 October 2019; Published: 17 October 2019


Abstract: The Plectranthus genus is commonly used in traditional medicine due to its potential to treat
several illnesses, including bacterial infections and cancer. As such, aiming to screen the antibacterial
and cytotoxic activities of extracts, sixteen selected Plectranthus species with medicinal potential were
studied. In total, 31 extracts obtained from 16 Plectranthus spp. were tested for their antibacterial
and anticancer properties. Well diffusion method was used for preliminary antibacterial screening.
The minimum inhibitory concentration (MIC) and minimal bactericidal concentration (MBC) values
of the five most active acetonic extracts (P. aliciae, P. japonicus, P. madagascariensis var. “Lynne”, P. stylesii,
and P. strigosus) were determined. After preliminary toxicity evaluation on Artemia salina L., their
cytotoxic properties were assessed on three human cancer cell lines (HCT116, MCF-7, and H460).
These were also selected for mechanism of resistance studies (on NCI-H460/R and DLD1-TxR cells).
An identified compound—parvifloron D—was tested in a pair of sensitive and MDR-Multidrug
resistance cancer cells (NCI-H460 and NCI-H460/R) and in normal bronchial fibroblasts MRC-5.
The chemical composition of the most active extract was studied through high performance liquid
chromatography with a diode array detector (HPLC-DAD/UV) and liquid chromatography–mass
spectrometry (LC–MS). Overall, P. strigosus acetonic extract showed the strongest antimicrobial and
cytotoxic potential that could be explained by the presence of parvifloron D, a highly cytotoxic
diterpene. This study provides valuable information on the use of the Plectranthus genus as a source
of bioactive compounds, namely P. strigosus with the potential active ingredient the parvifloron D.
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1. Introduction
The Plectranthus genus (Lamiaceae) comprises nearly 350 different species with a vast distribution
and is recognized for its rich bio- and ethnobotanical diversity [1–3] (see Supplementary Materials,
Figure S1). Its antibacterial, antifungal, antiviral, and antiproliferative potential have been well-described
in literature [2]. These characteristics contribute to its popular use in traditional medicine, mainly through
herbal preparations, thus having major importance in the provision of primary health care [3–5].
Cancer is still one of the major leading causes of death worldwide and the success of anticancer
therapies is dependent on the development of multidrug resistance (MDR) [5,6]. Plants have long been
used for the treatment of cancer and there are notable anticancer plant-derived drugs used in clinical
practice, namely vinca alkaloids (vinblastine and vincristine) and paclitaxel [7,8]. In addition, several
plant-derived products, namely terpenoids, and extracts have been described for their capability to
inhibit P-glycoprotein (P-gp), and thus modulate MDR [9].
Terpenoids are also considered as responsible for the antimicrobial properties attributed to the
aforementioned genus [3]. The increasing resistance to antibiotics and rising range of infections have
become a public health-concerning issue [10].
Diterpenes are frequently found in the Plectranthus genus and are compounds of high
interest, considering their wide spectrum of biological activity, characterized by antimicrobial and
anti-inflamatory activity, but also, anticancer properties [11]. The majority of diterpene metabolites
isolated from Plectranthus spp. belong to abietane, kaurane, and labdane classes [11]. The more prominent
functional groups are phenol or quinone diterpenes belonging to royleanone, coleon, or parvifloron
abietanes, which have been shown to be potent anticancer agent classes [12,13]. It is known that the major
component of the essential oil of P. madagascariensis is the diterpene 6,7 dehydroroyleanone, which is
easily identified due to its characteristic orange reddish color [14,15] and has already shown cytotoxic
properties [16,17]. On the other hand, it is also ascribed antitumoral activity by a number of other
Plectranthus species such as P. amboinicus, P. barbatus, and P. hadiensis [2], so the screening of their extracts
is a significant achievement. Other previous studies showed that natural compounds with antitumor
activity, isolated from Plectranthus, induce apoptosis by caspases activation. The discovery of natural
tumor-promoting phorbol esters acting as protein kinase C (PKC) activators led to a new interest in
the role of these proteins, but also, and more importantly, to new studies focusing on diterpenes as
PKC modulators. It is known that some of the PKC isoforms are implied in tumoral regression, while
others are involved in tumoral invasion, so modulating its activity is an important issue [18]. Having
this in mind, the present study was aimed at screening the antimicrobial and cytotoxic properties of
several Plectranthus spp. extracts. These goals were accomplished by comparing the efficacy of 31 plant
extracts and identifying the bioactive component responsible for the extracts activity.
2. Experimental
2.1. Plant Material
Plectranthus spp. (Lamiaceae family) were cultivated in Instituto Superior de Agronomia Campus
(Lisbon University), from seeds provided by the herbarium of the Botanical Garden of Lisbon,
Portugal. The air dried and powdered whole plants were selected based on their ethnopharmacological
features: Plectranthus aliciae (Codd) van Jaarsv. and Edwards, Plectranthus amboinicus (Lour.) Spreng.,
Plectranthus barbatus Andrews, P. ecklonii Benth., P. fruticosus L’Hér., Plectranthus hadiensis (Forssk.)
Schweinf. ex Spreng. var. hadiensis, P. hereroensis Engl., Plectranthus japonicus Koidz., Plectranthus
madagascariensis (Pers.) Benth. var. madagascariensis, P. madagascariensis (Pers.) Benth var. ‘Lynne’,
Plectranthus malvinus van Jaarsv. and T.J. Edwards, Plectranthus oertendahlii Th. Fr., Plectranthus reflexus
van Jaarsv. and T.J. Edwards, Plectranthus stylesii Edwards, P. strigosus Benth. ex E.Mey., and Plectranthus
zuluensis T. Cooke. The plant names were verified with the Index Kewensis [19]. The plants were grown
in Parque Botânico da Tapada da Ajuda from cuttings provided through the Kirstenbosch National
Botanical Gardens, South Africa; were collected between 2007 and 2008, always in June and September;
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and voucher specimens were deposited in the Herbarium “João de Carvalho e Vasconcellos” of the
“Instituto Superior de Agronomia”, Lisboa (LISI), Portugal [20].
Traditional uses of the mentioned plants and their voucher numbers are displayed in Table S1.
2.2. Extraction Procedure of Plectranthus spp.
Thirty-one extracts were prepared from sixteen different Plectranthus species. The air-dried leaves
of each plant were milled in a kitchen mill and weighed. The extraction procedure was carried out in
triplicate in an ultrasonic (US) bath (Bandelin SONOREX RK 510H, Berlin, Germany) for 60 min at
25 ◦C—using acetone, ethanol, and/or methanol—in a concentration of 10% (w/v). The suspensions
were then filtered using Filtrer Laurent—Prat demas 150 mm (Couze-St-Front, France). After each
filtration, the solvent was removed in a rotary evaporator (Sigma-Aldrich, IKA HBR 4 basic heating
bath, Essen, Germany) at 40 ◦C. After submitting the suspensions to ultrasounds three times, the final
extracts were weighed, and the yield of extraction determined. The percentage yield for each extract
was determined (Figure S2).
2.3. Microorganisms Used and Growth Conditions
Bacterial strains Enterococcus faecalis (ATCC 29212), Escherichia coli (ATCC 25922), Pseudomonas
aeruginosa (ATCC 27853), and Staphylococcus aureus (ATCC 25923), and yeast strains Candida albicans
(ATCC 10231) and Saccharomyces cerevisiae (ATCC 9763) were chosen based on their clinical and
pharmacological importance. In addition, S. cerevisiae was added due to its general toxicity screening
value. The tested bacteria were precultivated on Mueller Hinton agar and yeasts in Sabouraud agar
(Biokar diagnostics, Allonne, France). Cultures of microorganisms were grown at 37 ◦C (30 ◦C for the
yeasts) for 24 h and were maintained on respective agar slants at 4 ◦C.
2.4. Antimicrobial Screening Assays
2.4.1. Well Diffusion Method
The extracts were reconstituted in DMSO—Dimethyl Sulfoxide—to a 1 mg/mL concentration as
well as the stock solutions of reference antibiotics (vancomycin and norfloxacin, Gram-positive and
-negative, respectively). Nystatin was used as the positive control for the yeasts. Afterwards, Petri
dishes containing 20 mL of solid Mueller–Hinton culture medium (Sabouraud for the yeasts) were
inoculated with 100 µL of microorganism suspension (correspondent to a 0.5 McFarland standard
solution). The inocula were evenly harvested on the medium surface using a sterile swab [20]. Wells
of approximately 5 mm in diameter were punched aseptically in the medium, with a sterile glass
Pasteur pipette and 50 µL of each extract and antimicrobial agent were introduced into the well [20,21].
The solvent DMSO was used as negative control. Plates were then incubated at 37 ◦C (30 ◦C for
the yeasts) for 24 h. The antimicrobial activity was then evaluated by measuring the diameter (mm)
of the inhibition zone formed around the wells and the results compared to positive and negative
controls [20]. This method was tested at least in triplicate.
2.4.2. Determination of Minimum Inhibitory Concentration
Only extracts that showed inhibitory activity on the well diffusion method were tested for this
method, so only the bacteria were active. After screening the antimicrobial activity of the plant
extracts, the microplate broth microdilution method was performed for those that were considered
active (inhibition zone > 10 mm). As such, 100 µL of liquid Mueller–Hilton medium was distributed
in each well of a 96-well plate. The first well of each row contained 100 µL of extract, the positive
control, or negative control solutions (1 mg/mL concentration). Serial dilutions were made to 1:2
proportion between each row of wells (1.95–500 µg/mL range). Finally, 10 µL of bacterial suspension of
0.5 McFarland density were added to each well. Plates were then incubated at 37 ◦C for 24 h, allowing
the bacterial growth. The latter was measured with an absorbance microplate reader (Thermo Scientific
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Multiskan FC, Loughborough, UK) set to 620 nm. All assays were carried out in triplicate for each
tested microorganism [20].
2.4.3. Determination of Minimal Bactericidal Concentration
After concluding the minimum inhibitory concentration (MIC) assay, the minimal bactericidal
concentration (MBC) assay was done accordingly to the agar dilution method. Thus, a swab from each
well where no growth was observed—containing the tested extract concentration series—was plated
on a Mueller Hinton Agar [21–23]. The Petri plates were then incubated for 24 h at 37 ◦C, for further
evaluation. The lowest concentration that revealed no visible bacterial growth after subculturing was
taken as its MBC. Only the bacteria showed inhibition growth.
2.5. Cell Lines and Reagents
2.5.1. Chemicals
MTT (3-(4,5-dimethyl-2-thiazolyl)-2, 5-diphenyl-2H-tetrazolium bromide), rhodamine 123
(Rho123), and dimethylsulfoxide (DMSO) were acquired from Sigma-Aldrich Chemie GmbH. Fetal
bovine serum (FBS), RPMI 1640 medium (Roswell Park Memorial Institut), DMEM (Dulbecco’s Modified
Eagle Medium), penicillin–streptomycin solution, antibiotic–antimycotic solution, l-glutamine,
and trypsin/EDTA were purchased from PAA (Vienna, Austria).
2.5.2. Cell Culture Maintenance
Human colon (HCT116) and breast (MCF-7) adenocarcinoma, and non-small cell lung carcinoma
(NCI-H460) cell lines were purchase from ATCC. All cancer cells were cultured in RPMI-1640 medium
with ultraglutamine (Lonza, VWR, Carnaxide, Portugal), and supplemented with 10% fetal bovine
serum (FBS; Gibco, Alfagene, Carcavelos, Portugal). Cells were maintained at 37 ◦C in a humidified
atmosphere of 5% CO2.
Sensitive non-small cell lung carcinoma NCI-H460, colorectal carcinoma DLD1 cell lines,
and normal human embryonal bronchial fibroblasts MRC-5 were purchased from American Type
Culture Collection (Rockville, MD, USA).
NCI-H460 and DLD1 cells were maintained in RPMI 1640 medium containing 10% heat in
activated FBS, 2 mM l-glutamine, 4.5 g/L glucose, 10,000 U/mL penicillin, 10 mg/mL streptomycin,
and 25 mg/mL amphotericin B solution at 37 ◦C in a humidified 5% CO2 atmosphere. NCI-H460/R
cells were originally selected from NCI-H460 cells and cultured in a medium containing 100 nM
doxorubicin (DOX) [23]. DLD1-TxR cells were selected by continuous exposure to stepwise increasing
concentrations of paclitaxel (PTX) from DLD1 cells [24].
MRC-5 cells were cultured in DMEM supplemented with 10% FBS, 4 g/L glucose, l-glutamine
(2 mM), and 5000 U/mL penicillin, 5 mg/mL streptomycin solution at 37 ◦C in a humidified 5%
CO2 atmosphere.
All cell lines were subcultured at 72 h intervals using 0.25% trypsin/EDTA and seeded into a fresh
medium at the density of 8000 cells/cm2.
2.6. Preliminary Evaluation of General Toxicity on Artemia salina Model
Aiming at the evaluation of the preliminary toxicity of the selected Plectranthus spp. extracts,
a lethality test on Artemia salina L. was carried out [25]. The general toxicity on A. salina was tested
according to the method of Zhang et al. 2012 [26], with slight alterations.
Brine shrimp cysts (obtained from JBL GmbH and Co. KG, D-67141 Neuhofen Germany) were
hatched in artificial sea water with a concentration of 35 g/L. A container with two connected chambers
with a simple handmade communicating vessel was used for brine shrimp hatching. An air pump
inserted in the container ensured a regular air flow supply, thus saturating the artificial sea water for
successful hatching. The cysts were then incubated for 48 h at 24 ◦C. Each extract was tested at a
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concentration of 100 ppm. To do so, ten to fifteen nauplii were transferred into wells of 24-well plates
containing artificial sea water, and 100 µL of each extract was added to the wells (final volume per well:
1 mL). After 24 h exposure to the extracts (24 ◦C), the number of dead nauplii (mortality rate (%)) was
determined (Equation (1)). Also, LC50 (Lethal Concentration, 50%) values (µg/mL) were calculated for
the most toxic extracts. DMSO was used as the solvent and was kept at 10% (v/v) in all samples tested.
Mortality rate (%) =
Total nauplii−Alive nauplii
Total nauplii
(1)
2.7. Cytotoxicity Screening
Sulforhodamine B Assay for the Assessment of Extracts Effects
The effect of plant extracts on the in vitro growth of human tumor cell lines was evaluated using
the sulforhodamine B (SRB) assay, as described [27,28]. Briefly, cells were seeded in 96-well plates,
at a final density of 5.0 × 103 cells/well, and incubated for 24 h. Cells were then incubated with serial
dilutions of plant extracts (from 1.56 to 50 µg/mL) for 48 h. The solvent (DMSO) was used as negative
control at the same concentration as the maximum tested in the assay. The concentration of compound
that causes a 50% reduction in the net protein increase in cells during treatment (GI50, growth inhibition
of 50%) was subsequently calculated.
NCI-H460, NCI-H460/R, DLD1, and DLD1-TxR cells grown in 25 cm2 tissue flasks were trypsinized,
seeded into flat-bottomed 96-well tissue culture plates (2 × 104 cells/well), and incubated overnight.
Treatments with extracts (5–100 µg/mL) lasted 72 h. The cellular proteins were stained with SRB,
following slightly modified protocol of Skehan et al. [28]. Briefly, the cells in 96-well plates were fixed
in 50% trichloracetic acid (50 µL/well) for 1 h at 4 ◦C, rinsed in tap water, and stained with 0.4% (w/v).
SRB in 1% acetic acid (50 µL/well) for 30 min at room temperature. The cells were then rinsed
three times in 1% acetic acid to remove the unbound stain. The protein-bound stain was extracted with
200 µL 10 mM Tris base (pH 10.5) per well. The optical density was read at 540 nm with correction
at 670 nm in a LKB 5060-006 Micro plate Reader (Vienna, Austria). The concentration of each drug
that inhibited cell growth by 50%. (IC50) was calculated by nonlinear regression analysis using log
(inhibitor) vs. normalized response in GraphPad Prism 6 software. Values represent means ± SE
(Standard Error) from at least three independent experiments, each performed in triplicate.
2.8. Liquid Chromatography–Mass Spectrometry Analysis
Liquid chromatography–mass spectrometry (LC–MS)/MS analyses were performed on a Waters
Alliance 2695 high performance liquid chromatography (HPLC) separation module connected to a
Micromass Quattro Micro triple Quadropole (Waters, Dublin, Ireland) Mass Spectrometer equipped
with a Waters electrospray ionization (ESI) source. Mass spectrometer was operated in positive mode
and spectra were recorded in the m/z 60 to 800 Da range. In order to optimize detection conditions,
a standard solution of parvifloron D was infused in the mass spectrometer and capillary and cone
voltages, and collision energy were tuned to maximize (recursor ion > product ion) transition signal.
ESI capillary voltage was optimized to 3 kV, cone voltage was set on 30 V. Source and desolvation
temperature were adjusted to 120 ◦C and 350 ◦C, respectively. High purity nitrogen (N2) was used as
drying gas and as a nebulizing gas. Ultra-high purity argon (Ar) was used as collision gas. A reversed
phase WatersTM Atlantis C-18 (Waters, Milford, MA, USA; 5 µm × 2.1 mm × 150 mm) was used,
with an injection volume of 15 µL. The mobile phase consisted in 0.5% formic acid in Milli-Q water
(eluent A) and acetonitrile (eluent B). A flow rate of 0.2 mL/min was used, with the following gradient
program: 0–15 min from 60% to 20% A, 15–20 min at 20% A, 20–30 min 60% A. MassLynx software
(Waters, version 4.1) was used for data acquisition and processing.
The quantification of the identified compound was carried out in an Agilent Technologies
1200 Infinity Series system with diode array detector (DAD; Agilent, Santa Clara, CA, USA), equipped
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with a Zorbax XDB-C18, (250 × 4.0 mm i.d., 5µm) column, from Merck and ChemStation Software
(Hewlett-Packard, Alto Palo, CA, USA). Each extract was analyzed (after 20 µL injection) and a
gradient elution mixture composed of solution A (methanol), solution B (acetonitrile), and solution C
(0.3% trichloroacetic acid in water) was used as follows: 0 min, 15% A, 5% B, and 80% C; 20 min, 70% A,
30% B, and 0% C; 25 min, 70% A, 30% B, and 0% C; and 28 min, 15% A, 5% B, and 80% C. The flow
rate was set at 1 mL.min−1. For quantification and identification purposes, the compounds present
in the samples were compared with calibration standards. Compound identification was based on
ultraviolet (UV) spectra comparison and retention time. The time of analysis was of 28 min, including
the stabilization of the RP-18 column. All analyses were performed in triplicate.
2.9. Anticancer Effects of the Identified Compound
The anticancer properties of the parvifloron D present in the most active extract were assessed
through the use of a model system of NCI-H460 and its resistant counterpart NCI-H460/R, along with
normal human embryonal bronchial fibroblasts MRC-5. MTT test was applied after 72 h incubation
with diterpenes, applied within a range of concentrations 2.5–50 µM.
2.9.1. Cell Viability Assessed by MTT Assay
MTT assay is based on the reduction of 3-(4, 5-dimethyl-2-thizolyl)-2,5-diphenyl-2H-tetrazolium
bromide into formazan dye by active mitochondria of living cells. Briefly, cells grown in 25 cm2
tissue flasks were trypsinized, seeded in 96-well tissue culture plates (2,000 cells/well), and incubated
overnight in 100 mL of appropriate medium. After 24 h, cells were treated with increasing concentrations
of parvifloron D (2.5–50 µM). All treatments lasted 72 h. At the end of treatment period, 100 mL of
MTT solution (1 mg/mL) was added to each well and plates were incubated at 37 ◦C for 4 h. Formazan
product was dissolved in 200 mL DMSO. The absorbance of obtained dye was measured at 540 nm
using an automatic microplate reader (LKB 5060-006 Micro Plate Reader, Vienna, Austria).
Relative cell growth rate (CG) was determined according to the following equitation:
CG (%) = (A treated sample/A untreated control) × 100, (2)
where A is absorbance. IC50 value was defined as concentration of each drug that inhibited cell growth
by 50%. IC50 was calculated by nonlinear regression analysis using log (inhibitor) vs. normalized
response in GraphPad Prism 6 software.
2.9.2. Assay for P-gp Inhibiting Activity
The function of P-gp was analyzed by flow-cytometry utilizing the ability of its substrate Rho123
to emit fluorescence. Studies were carried out with parvifloron D. Dex-VER was used as a positive
control. The MDR cells (NCI-H460/R) were grown to 80% confluence in 75 cm2 flasks, trypsinized,
and resuspended in 5 mL centrifuge tubes in a Rho123-containing medium (5 µM Rho123). The cells
were treated with Dex-VER and parvifloron D (5 µM) and incubated at 37 ◦C in 5% CO2 for 30 mmL of
cold phosphate-buffered saline, and analyzed usinin. The samples were washed twice, resuspended in
1.0 g CyFlow Space flow cytometer (Partec, Münster, Germany). The mean fluorescence intensity (MFI)
of Rho123 was assessed on fluorescence channel 1. At least 10,000 events were assayed for each sample.
2.9.3. Effects of Compounds on Microtubule
The effect of the identified compound on interphase on microtubules, mitotic spindles, nuclear
morphology, and cell cycle was assessed. In order to do so, human lung carcinoma A549 cells were
incubated for 20 h with serial concentrations of the diterpene ranging from 10 nM to 200 µM.
The DNA content was analyzed by flow cytometry using a BD FACSVerseTM cytometer
(BD Biosciences, San Jose, CA, USA). Cells were collected and centrifuged at 500× g, washed with
phosphate buffer saline (PBS), and resuspended in 50 µL of PBS. Following dropwise addition of 1 mL
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of ice-cold 75% ethanol, fixed cells were stored at −20 ◦C for 1 h. Samples were then centrifuged at
500× g and washed with PBS before resuspension in 1 mL of PBS containing 50 µg/mL propidium
iodide and 100 µg/mL RNase A, and incubation for 1 h at 37 ◦C in the dark. The percentage of cells
with decreased DNA staining, composed of apoptotic cells resulting from either fragmentation or
decreased chromatin, was counted (minimum of 10,000 cells per experimental condition). Cell debris
was excluded from analysis by selective gating based on anterior and right angle scattering.
3. Results and Discussion
The acetonic, ethanolic, and/or methanolic extracts of several Plectranthus species (Figure S1) were
evaluated concerning their antimicrobial activity through the well diffusion method and further MIC
and MBC determination. Furthermore, in order to evaluate their cytotoxic properties, toxicity assays
were performed on Artemia salina L. and different cancer cell lines.
All 31 extracts were screened at a fixed concentration (1 mg/mL). Overall, five extracts demonstrated
inhibitory activities against either or both Enterococcus faecalis (ATCC 29212) and Staphylococcus aureus
(ATCC 25923) bacterial strains (Table S2). All other extracts did not display antibacterial effects,
showing inhibition zones lower than 10 mm (data not shown). The extracts prepared with acetone
revealed better antimicrobial activity, particularly against Gram-positive bacteria.
A significant inhibition zone was recorded for the acetonic extracts of P. aliciae and P. madagascariensis
var. “Lynne”, for both Gram-positive bacteria used (E.faecalis and S. aureus), with results similar to those
of positive control. The remaining active extracts, however, showed selectivity only against S. aureus.
Regarding the results obtained on the well diffusion test, only Gram-positive bacteria were taken
into account on these assays. Thus, in order to assess the lowest growth inhibitory concentration of
the most promising Plectranthus spp. extracts, minimum inhibitory concentration values (MIC) were
determined. Their bacteriostatic and bactericidal properties were also evaluated (Table 1) MIC values
ranged from 15.6 to 125 µg/mL, while MBC values ranged from >62.5 to 250 µg/mL.
Table 1. Minimum inhibitory concentration (MIC) and minimum bactericidal concentration (MBC)
values of Plectranthus spp. acetonic extracts against tested bacteria (results expressed in µg/mL).
Acetonic Extracts
Gram-Positive Bacteria
E. faecalis (ATCC 29212) S. aureus (ATCC 25923)
MIC MBC MIC MBC
P. aliciae 15.6 125 62.5 125
P. japonicus 62.5 125 62.5 125
P. madagascariensis ‘Lynne’ 15.6 >125 125 125
P. strigosus 15.6 >62.5 125 125
P. stylesii 31.3 >125 62.5 250
Positive control (VAN) 1.95 7.82
Negative control (DMSO) >500 >500
VAN—vancomycin (1 mg/mL); NOR—norfloxacin (1 mg/mL).
Comparing the MBC and MIC values of the selected extracts, and having in mind that a bactericidal
effect is associated to a MBC no more than four times the MIC value [21], it is possible to conclude that
the extracts are mainly bactericidal rather than bacteriostatic.
The preliminary evaluation of toxicity on Artemia salina is a fairly easy and inexpensive method
and is particularly interesting when testing plant extracts as it can be used as a prescreen of their
potential antitumor activities This assay also helps in gaining a preliminary understanding of which
extracts may deserve additional testing. All 31 extracts were tested (data not shown), but only five
of them exhibited toxic effects with values ranging from 13.62 to 110.76 µg/mL (Table 2). Curiously,
these five acetonic extracts were the same that induced S. aureus growth inhibition. The lowest LC50,
and consequently, the highest toxic potential, was attributed, once again, to the activity of P. strigosus.
On the contrary, the least toxic extract was attributed to P. stylesii.
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Table 2. A. salina general toxicity results LC50 (µg/mL) of acetonic extracts of the selected Plectranthus spp.
Acetonic Extracts Mortality Rate (%) at 100 ppm Concentration LC50 (µg/mL)
P. aliciae 16.71 ± 1.01 53.48
P. japonicus 21.85 ± 0.35 38.9
P. madagascariensis var “Lynne” 9.67 ± 0.93 91.7
P. stylesii 16.30 ± 0.99 110.76
P. strigosus 42.88 ± 2. 21 13.62
DMSO 22.50 ± 3.54 N.A.
N.A.—non applicable.
The GI50 values were also determined for each of the 31 extracts, in HCT116, MCF-7, and NCI-H460
cell lines, and the observed reduction in the cell growth was compared to the growth of cells treated
with DMSO only (set as 100% growth). The results are summarized in Figure 1 below. The data bars
not shown refer to a GI50 value equal or higher than 50 µg/mL.
Biomolecules 2019, 9, x FOR PEER REVIEW  8 of 14 
Table 2. A. salina general toxicity results LC50 (µg/mL) of acetonic extracts of the selected Plectranthus 
spp. 
Ac tonic Extracts Mortality Rate (%) at 100 ppm Concentration LC50 (μg/mL) 
P. aliciae 16.71 ± 1.01 53.48 
P. japonicus 21.85 ± 0.35 38.9 
P. madagascariensis var “Lynne” 9.67 ± 0.93 91.7 
P. stylesii 16.30 ± 0.99 110.76 
P. strigosus 42.88 ± 2. 21 13.62 
DMSO 22.50 ± 3.54 N.A. 
N.A.—non applicable. 
The GI50 values we  also determin d for each of the 31 extracts, in HCT116, MCF-7, and NCI-
H460 cell lines, and the observed reduction in the cell growth was compared to the growth of cells 
treated with DMSO only (set as 100% growth). The results are summarized in Figure 1 below. The 
data bars not shown refer to a GI50 value equal or higher than 50 µg/mL. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Growth inhibition of 50% (GI50) values (µg/mL) of Plectranthus spp. extracts in HCT116 (a), 
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Figure 1. Growth inhibition of 50% (GI50) values (µg/mL) of Plectranthus spp. extracts in HCT116 (a),
MCF-7 (b), and NCI-H460 (c) cells were determined after 48 h treatment using the SRB assay. Data
are mean ± SEM (n = 3,4). Doxorubicin was used as a positive control (GI50: 54.00 ± 3.24 ng/mL in
HCT116, 85.17 ± 4.10 ng/mL in MCF-7, 292.01 ± 2.32 ng/mL in NCI-H460 cells).
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According to the results, acetonic extracts revealed better cytotoxic effects. Five of these—P. aliciae,
P. japonicus, P. madagascariensis var. “Lynne”, P. stylesii, and P. strigosus—have consistently exhibited a
broad cytotoxic potential. When analyzing GI50 on the three tested cell lines, values ranged between
3.47 to 16.67 µg/mL, showing effective growth inhibition against specific cell lines.
P. strigosus acetonic extract displayed the highest overall anticancer potential, given its growth
inhibitory activities towards HCT116 (GI50 = 3.78 ± 0.49 µg/mL), MCF-7 (GI50 = 8.35 ± 0.57µg/mL),
and NCI-H460 (GI50 = 8.75 ± 0.70 µg/mL). On the other hand, the highest inhibitory growth activities
on MCF-7 and NCI-H460 cell lines were attributed to the effect of P. madagascariensis var. “Lynne”
(GI50 = 3.47 ± 0.15µg/mL and 5.39 ± 0.48, respectively).
The extract with the lowest anticancer potential was P. reflexus methanolic extract, for which GI50
was not reached in the screened range in all tested cell lines (GI50 ≥ 50 µg/mL).
Overall, Plectranthus spp. extracts recorded a broader cytotoxic activity against HCT116, given
that 27 out of the 31 extracts tested have GI50 lower than 50 µg/mL.
According to the results obtained in the previous screening (Figure 1), the most promising
Plectranthus spp. extracts were tested in MDR cell lines with P-gp overexpression: NCI-H460/R
(non-small cell lung carcinoma cell line) and DLD1-TxR (colorectal adenocarcinoma cell line). The effects
of the five selected acetonic extracts were assessed by SRB assay after 72 h, and their IC50 values were
determined (Figure 2). P. strigosus acetonic extract exerted an overall best effect in both non-small
cell lung carcinoma and colorectal adenocarcinoma cells, which showed IC50 values of 5.64 µg/mL
(NCI-H460), 11.09 µg/mL (NCI-H460/R), 2.41 µg/mL (DLD1), and 2.51 µg/mL (DLD1-TxR).
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cells to acetonic Plectranthus extracts. The IC50 (half maximal inhibitory concentration) was determined
using SRB assay after 72 h treatment with aceto ic extracts. Statistical analysis was performed in
GraphPad Prism 6 by two-way ANOVA: *** indicates the resistance to the specific extract (p < 0.001);
### indicates the collateral sensitivity to the specific extract (p < 0.001).
All five extracts exerted similar results towards colorectal adenocarcinoma cells (DLD1 and
DLD1-TxR). Thus, their efficacy might not depend on the presence of a MDR phenotype. Acetonic
extracts from P. aliciae, P. japonicas, and P. strigosus were less active against non-small cell lung carcinoma
MDR cells (NCI-H460/R) in comparison with their sensitive counterparts (NCI-H460). Interestingly,
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resistant NCI-H460/R were more sensitive to extracts from P. malvinus and P. stylesii showing collateral
sensitivity, the phenomenon when MDR cells are more vulnerable than corresponding sensitive cells.
In order to assess the chemical composition of the most active extract (P. strigosus acetonic extract),
and in an attempt to identify the compounds responsible for the referred activity, a combination of
HPLC–DAD (diode array detector) –MS techniques were carried out. The HPLC–MS analysis showed
two main peaks at 19.8 and 22.0 min, which revealed a UV spectrum characteristic of quinone methide
diterpenes [29]. The ESI mass spectra of the compounds pointed to the presence of parvifloron E or F
(peak at 19.8 min, m/z 451 [M + H]+) and parvifloron D (peak at 22 min, m/z 435 [M + H]+). The presence
of parvifloron D was confirmed through MS/MS analysis by comparison with a standard compound.
MS/MS spectra showed product ions at m/z 297 (base peak) and m/z 279, corresponding to the loss
of the ester moiety ([M-C7H5O3 + H]+) and ester moiety and H2O ([M-C7H5O3-H2O + H]+), see
Supplementary Materials, Figure S3. The 19.8 min compound displayed a similar fragmentation pattern
corresponding to the same diterpenic scaffold, with one more hydroxyl group on the aromatic ring
substituent. Therefore, this compound was tentatively identified as parvifloron F. The quantification of
parvifloron D was performed through HPLC–DAD/UV and was found to be present in the acetonic
extract of P. strigosus with a relative concentration of 9%.
Given its antitumor properties [30], the presence of the latter may explain, to a certain extent,
the foreseen toxic properties of P. strigosus acetonic extract. In order to further explore its cytotoxicity,
additional studies were performed on this compound.
Afterwards, the preliminary toxicity evaluation of parvifloron D on Artemia salina L. resulted in a
76.6% mortality rate on this species after 24 h incubation.
In addition, its cytotoxic activity was further evaluated on NCI-H460 and NCI-H460/R cell lines.
To determine whether parvifloron D is selective towards cancer cells, the cytotoxic effect in normal
embryonic bronchial fibroblasts (MRC-5) was also evaluated.
As expected, this diterpene demonstrated high cytoxicity and exerted a similar activity in all
three cell lines, with IC50 ranging from 1.7 to 1.9 µM. Interestingly, it also showed the same efficacy in
sensitive and MDR cancer cells, which implies that parvifloron D is able to evade P-gp eﬄux activity
(Figure 3A). However, it was equally active against normal cells (Figure 3A). Parvifloron D was also
tested regarding its potential to inhibit P-gp activity in NCI-H460/R cells. Unfortunately, parvifloron D
was not able to increase the Rhodamine 123 accumulation in P-gp overexpressing cells (Figure 3B).
Considering its high cytotoxic potential, further examinations of parvifloron D should be performed.
Its mechanism in cancer and normal cells, with respect to the application of lower concentrations and
different time scheduling, are necessary to clarify whether this compound should be developed as an
anticancer agent.
In order to check whether this abietane diterpene was a microtubule stabilizer agent, A549
cell morphologies in the IC50 culture plates were examined with an inverted microscope, after 20 h
incubation with parvifloron D. Paclitaxel was used as control tubulin specific drug. All microtubule
targeting drugs, stabilizers, or depolymerizers in contact with A549 cell lines induced the appearance of
round cells (mitotic cells) that detach from the plate. However, parvifloron D only displayed a cytotoxic
effect rather than cytostatic, with no mitotic blockage, practically ruling out an action on mitotic spindle
microtubules (data not shown). These results suggest that the antibacterial and anticancer activities of
the acetonic extract of P. strigosus are attributed to the presence of parvifloron D. These results correlate
to the representative HPLC–DAD/UV (λ = 254 nm) chromatogram of acetonic extract of P. strigosus and
UV DAD spectra of peaks. The prepared acetonic extract of P. strigosus (c = 0.67 mg/mL) was revealed
to have Parvifloron D (9% (w/w) in its composition.
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4. Conclusions
Overall, the screening of the Plectranthus spp. through several extracts carried out in this work was
motivated by the possibility of enlighteni g the cytotoxic ctivities of these species. Acetone extracts
have be n proven to possess higher overall antimicrob al and cytotoxic activity. Comparing the results
of the well diffusion method with the corresponding GI50 (µg/mL) values obtained in cancer cells,
it can be concluded that the extracts with antimicrobial properties in S. aureus were also those with
the lowest GI50 values. Therefore, among the 31 Plectranthus spp. extracts, the acetonic extracts from
P. aliciae, P. japonicus, P. malvinus van Jaarsv. and T.J. Edwards, P. strigosus, and P. stylesii were selected
as promising candidates for further examination. To the best of our knowledge, this study provides the
first insight on the biological activities of some Plectranthus spp. such as P. aliciae, P. madagascariensis var.
“Lynne”, and P. stylesii. More importantly, it has also allowed the assignment of components that might
be responsible for their activity, such as the abietane diterpene parvifloron D. Overall, the acetonic
extract of P. strigosus revealed the best cytotoxic potential.
For the reasons mentioned above, the results demo strated that the Plectranthu genus may
contain therapeutically useful compounds against both Gram-positive bacteria and some solid cancer
cell lines including those with MDR phenotype.
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Parvifloron D Mass Spectroscopy spectra (MS/MS spectra).
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